Rohto Pharmaceutical Co.,Ltd. (TYO:4527)

Rohto Pharmaceutical Financials Overview

Financials in millions JPY. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	343,725	343,725	308,625	270,840	238,664	199,646
Revenue Growth	11.37%	11.37%	13.95%	13.48%	19.54%	10.13%
Gross Profit Gross Profit Growth	192,695	192,695	174,939	157,286	137,421	116,489
Operating Income Operating Income Growth	40,706	40,706	38,465	40,167	33,538	28,192
Net Income Net Income Growth	34,247	34,247	31,006	30,936	26,377	21,018
Earnings Per Share EPS Growth	145.29	145.29	135.44	135.21	115.29	91.86
EPS Growth	7.27%	7.27%	0.17%	17.28%	25.50%	25.53%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Others Others Growth	3,689	3,689	3,451	2,830	2,381	1,964
Unallocated Adjustment Unallocated Adjustment Growth	-12,321	-12,321	-11,442	-9,357	-8,947	-7,565
Americas Americas Growth	23,156	23,156	22,593	20,074	18,076	11,187
Japan Japan Growth	173,997	173,997	168,852	160,168	140,510	124,800
Europe Europe Growth	24,093	24,093	19,334	14,015	12,247	10,344
Asia Asia Growth	131,109	131,109	105,835	83,108	74,395	58,915
Total Total Growth	343,723	343,723	308,623	270,838	238,662	199,645

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	86,816	86,816	77,161	89,210	79,951	72,791
Total Debt Total Debt Growth	60,244	60,244	50,223	10,494	11,693	21,383
Net Cash (Debt) Net Cash Growth	26,572	26,572	26,938	78,716	68,258	51,408
Net Cash Growth	-1.36%	-1.36%	-65.78%	15.32%	32.78%	14.58%
Net Cash Per Share Net Cash Per Share Growth	112.85	112.85	117.69	344.04	298.33	224.69

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	47,788	47,788	36,917	34,245	30,924	27,250
Capital Expenditures CapEx Growth	-11,494	-11,494	-9,080	-7,979	-8,473	-10,267
Free Cash Flow Free Cash Flow Growth	36,294	36,294	27,837	26,266	22,451	16,983
Free Cash Flow Growth	30.38%	30.38%	5.98%	16.99%	32.20%	50.47%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	56.06%	56.06%	56.68%	58.07%	57.58%	58.35%
Operating Margin	11.84%	11.84%	12.46%	14.83%	14.05%	14.12%
Pretax Margin	13.62%	13.62%	13.72%	15.33%	14.37%	14.00%
Profit Margin	9.96%	9.96%	10.05%	11.42%	11.05%	10.53%
FCF Margin	10.56%	10.56%	9.02%	9.70%	9.41%	8.51%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 1, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	50.000	46.000	36.000	27.000	22.000	18.000
Dividend Per Share Growth	21.95%	27.78%	33.33%	22.73%	22.22%	28.57%
Dividend Yield	2.09%	1.91%	1.64%	0.94%	0.83%	1.02%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 1, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	16.44	15.89	16.30	21.88	23.96	20.05
Forward PE	15.36	16.34	15.19	20.08	24.15	19.94
P/FCF Ratio	14.87	14.99	18.16	25.77	28.15	24.82
PS Ratio	1.57	1.58	1.64	2.50	2.65	2.11

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error